期刊文献+

脑血栓患者凝血因子Ⅻ对纤溶活性影响的初步研究 被引量:6

Preliminary study on the effects of coagulation factor Ⅻ on fibrinolysis
原文传递
导出
摘要 目的 研究脑血栓和 (或 )脑腔隙性梗死 (脑腔梗 )患者中凝血因子Ⅻ (FⅫ )对纤溶的影响。方法 用ELISA方法检测脑血栓患者血浆FⅫ∶Ag、FⅫa、βFⅫa水平 ,FⅫ∶C和其他纤溶活性 ;利用MOEA技术筛选是否存在已知常见的FⅫ基因点突变。结果  10 7例脑血栓患者中 ,有 2 2例呈FⅫ∶C下降 ,类似FⅫCRM+表现 ,PLG∶A、α2 AP∶A升高和D 二聚体 (D D)水平降低的同时 ,FⅫa和βFⅫa水平明显降低 ;2 2例FⅫ∶C下降患者均未见已知的FⅫ基因突变。结论 FⅫ∶C下降可能通过降低纤溶酶原的活性 ,在脑血栓形成中发挥重要作用 ;类似FⅫCRM+的FⅫ异常 ,其基因突变与已知基因突变不同 ;FⅫ 334精氨酸、35 3精氨酸所在区域相应的基因点突变可能对FⅫa、βFⅫa水平和纤溶活性下降更重要。 Objective To study the effects of FⅫ on fibrinolysis in patients with cerebral thrombosis. Methods Plasma level of FⅫ∶C, FⅫ∶Ag, FⅫa and β FⅫa and fibrinolysis activities were examined by ELISA. Screening of FⅫ gene mutation by MOEA. Results FⅫ∶C in 22 of 107 patients with cerebral thrombosis decreased, which was similar to the feature of FⅫ cross reacting material positive (FⅫ CRM +). There were significant increase in plasma levels of PLG∶A and α 2AP∶A and decrease in D dimer, moreover, plasma levels of FⅫa and βFⅫa were lower in patients than in controls. FⅫ gene mutation was not found in 22 of 107 patients. Conclusion Decrease of FⅫ∶C may play an important role in cerebral thrombosis by reducing activation of plasminogen. The gene mutation of FⅫ CRM + like abnormal FⅫ was different from the known FⅫ gene mutation. Mutations in the regions of FⅫ Arg (334) and Arg(353) may be more important for the reducing of FⅫa、β FⅫa levels and fibrinolysis activities. FⅫ assay should be included in thrombotic disorder screening.
出处 《中华血液学杂志》 CAS CSCD 北大核心 2000年第9期466-468,共3页 Chinese Journal of Hematology
关键词 脑血栓形成 凝血因子Ⅻ 纤维溶性 基因突变 Blood coagulation factor Ⅻ Thrombosis Fibrinolysis Gene mutation
  • 引文网络
  • 相关文献

参考文献3

  • 1王鸿利.血液学与血液学检验(第2版)[M].北京:人民卫生出版社,1997.236-248.
  • 2李家增,血液实验学,1997年,356-359,366-368,421-页
  • 3王鸿利,血液学和血液学检验(第2版),1997年,236页

同被引文献39

  • 1Michael L,Murat T,John K,et al.Laboratory evaluation of hypercoagulable states in patients with central retinal vein occlusion who are less than 56 years of age[J].Ophthalmology,2002,109:126-131.
  • 2Prisco D,Marcucci R.Retinal vein thrombosis:risk factors,pathogenesis and therapeutic approach[J].Pathophysiol Haemost Thromb,2002,32(5-6):308-311.
  • 3Prisco D,Marcucci R,Bertini L,et al.Cardiovascular and thrombophilic risk factors for central retinal vein occlusion[J].Eur J Intern Med,2002,13(3):163-169.
  • 4Lahey JM,Kearney JJ,Tunc M.Hypercoagulable states and central retinal vein occlusion[J].Curr Opin Pulm Med,2003,9(5):385-392.
  • 5van Cott EM,Laposata M,Hartnett ME.Prothrombin gene mutation G20210A,homocysteine,antiphospholipid antibodies and other hypercoagulable states in ocular thrombosis[J].Blood Coagul Fibrinolysis,2004,15(5):393-397.
  • 6Speicher L,Philipp W,Kunz FJ.Factor Ⅻ deficiency and central retinal vein occlusion[J].Lancet,1992,340(8813):237.
  • 7Abu El-Asrar AM,Abdel Gader AG,Al-Amro S,et al.Hypercoagulable states in patients with retinal venous occlusion[J].Doc Ophthalmol,1998,95(2):133-143.
  • 8Bashshur ZF,Taher A,Masri AF,et al.Anticardiolipin antibodies in patients with retinal vein occlusion and no risk factors:a prospective study[J].Retina,2003,23(4):486-490.
  • 9Bick RL,Baker WF.Antiphospholipid and thrombosis syndromes[J].Semin Thromb Hemost,1994,20:3-15.
  • 10Ratnoff OD,Colopy JE.A femilial hemorrhagic trait associated with a deficiency of a clot-promoting fraction of plasma[J].J Clin Invest,1955,34(4):602-613.

引证文献6

二级引证文献12

;
使用帮助 返回顶部